Samsara BioCapital’s Urovant Sciences Ltd. UROV Stock Holding History

Samsara BioCapital’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-157,480	Closed	-$1.47M	–	45
2020 Q3	$1.47M	Hold	157,480	–	–	0.41%	31
2020 Q2	$1.55M	Hold	157,480	–	–	0.5%	27
2020 Q1	$1.45M	Hold	157,480	–	–	0.84%	21
2019 Q4	$2.44M	Hold	157,480	–	–	1.17%	16
2019 Q3	$1.49M	Hold	157,480	–	–	1.01%	14
2019 Q2	$1.25M	Hold	157,480	–	–	0.82%	16
2019 Q1	$1.58M	Hold	157,480	–	–	1.24%	14
2018 Q4	$1.04M	Buy	+157,480	New	+$1.43M	1%	13

Other funds holding UROV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Samsara BioCapital's UROV Position: Q4 2020 in Review

Samsara BioCapital sold out of Urovant Sciences Ltd. (UROV) in Q4 2020, closing a stake of 157,480 shares — an estimated $1.47M sold.

Samsara BioCapital first reported a position in UROV in Q4 2018 and held it in 8 quarters. The position peaked at $2.44M in Q4 2019. 41 funds tracked by Wall St. Rank hold UROV as of Q4 2020.

Samsara BioCapital reported no remaining Urovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
Samsara BioCapital sold 157,480 Urovant Sciences Ltd. shares in Q4 2020, an estimated $1.47M.
Samsara BioCapital first reported a position in Urovant Sciences Ltd. in Q4 2018 and held it in 8 quarters.
Samsara BioCapital's Urovant Sciences Ltd. position peaked at $2.44M in Q4 2019.
41 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2020.

Based on Samsara BioCapital's 13F filing for Q4 2020, filed 17 Feb 2021.